Bristol Myers Squibb (BMY) Stock Forecast & Price Target

Bristol Myers Squibb
Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

• Bristol-Myers Squibb recently reported strong second-quarter results, beating analyst expectations with earnings per share of $2.04 compared to the consensus estimate of $1.60, while revenue of $12.97 billion also exceeded the projected $11.74 billion, signaling robust operational performance and potential for continued earnings growth.
• The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma, which serves as a new oncology growth driver and helps diversify the company's product portfolio beyond its existing franchises.
• Bristol-Myers Squibb offers a dividend yield of 3.78%, providing a steady income stream for investors, supported by a payout ratio of 55.51% which suggests the company retains sufficient earnings to maintain this distribution while funding operations.
• The stock is currently trading at $66.72, which is near the consensus price target of $66.0556 and significantly above the 52-week low of $42.52, indicating that the market has already priced in much of the recent positive news while the "Moderate Buy" consensus rating suggests further upside potential.
• Bristol-Myers Squibb presented long-term data at the European Society of Cardiology Congress 2026 reinforcing the efficacy and safety of Camzyos (mavacamten) for symptomatic obstructive hypertrophic cardiomyopathy, which supports the long-term commercial viability of this cardiovascular franchise.